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TestosteroneThis article is part of a Special Issue "Hormones & Neurotrauma".
Astrocytes and microglia respond to central nervous system (CNS) injury with changes in morphology, pro-
liferation, migration and expression of inflammatory regulators. This phenomenon is known as reactive glio-
sis. Activation of astrocytes and microglia after acute neural insults, such as stroke or traumatic CNS injury, is
considered to be an adaptive response that contributes to minimize neuronal damage. However, reactive
gliosis may amplify CNS damage under chronic neurodegenerative conditions. Progesterone, estradiol and
testosterone have been shown to control reactive gliosis in different models of CNS injury, modifying the
number of reactive astrocytes and reactive microglia and the expression of anti-inflammatory and proinflam-
matory mediators. The actions of gonadal hormones on reactive gliosis involve different mechanisms, includ-
ing the modulation of the activity of steroid receptors, such as estrogen receptors α and β, the regulation of
nuclear factor-κB mediated transcription of inflammatory molecules and the recruitment of the transcrip-
tional corepressor c-terminal binding protein to proinflammatory promoters. In addition, the Parkinson's dis-
ease related gene parkin and the endocannabinoid system also participate in the regulation of reactive gliosis
by estradiol. The control exerted by gonadal hormones on reactive gliosis may affect the response of neural
tissue to trauma and neurodegeneration and may contribute to sex differences in the manifestation of neu-
rodegenerative diseases. However, the precise functional consequences of the regulation of reactive gliosis
by gonadal hormones under acute and chronic neurodegenerative conditions are still not fully clarified.
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The brain and the endocrine glands maintain a permanent cross-
talk to regulate the homeodynamic equilibrium in the organism.
The brain modulates the activity of the endocrine glands and in
turn, hormonal secretions regulate the function of the central nervousnida Doctor Arce 37; E-28002
ra).
l rights reserved.system not only under physiological conditions but also under dis-
ease states (Garcia-Segura, 2009). Accordingly, several hormones
have been shown to modulate the response of neural tissue to injury
and to exert protective or reparative roles in the central nervous
system (CNS). Among these hormones, the neuroprotective actions
of gonadal steroids have received considerable attention and
the mechanisms involved in these actions have been studied with
considerable detail.
Neurons are direct targets for the neuroprotective actions of
gonadal steroids. Indeed, studies in primary neuronal cultures, in
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protective actions on neurons. However, in vivo, gonadal hormones
coordinate neuron–glia interactions (Garcia-Ovejero et al., 2005;
McAsey et al., 2006; Struble et al., 2007; Azcoitia et al., 2010) and
have complementary neuroprotective mechanisms, acting on the
neurovascular unit and regulating reactive gliosis and neuroinflam-
mation (Garcia-Estrada et al., 1993; Barreto et al., 2007; Brown
et al., 2010; Saraceno et al., 2010; Labombarda et al., 2011).
Reactive gliosis is a complex phenomenon involving the activation
and proliferation of microglia and astroglia and the migration of these
cells towards the sites of injury (Sofroniew, 2009; Graeber and Streit,
2010; Lull and Block, 2010). Other cell types, such as endothelial cells,
NG2 cells and oligodendrocytes are also affected by neurodegenerative
stimuli and by the activity of astrocytes and microglia. In addition, the
activation of astrocytes and microglia during reactive gliosis is accom-
panied with modifications in the local release of chemokines and cyto-
kines, which regulate the inflammatory process. Reactive astrocytes
suffer a continuum of progressive and multiple modifications in gene
expression and cellularmorphology that depend on the cellular context
and the severity of the insult (Sofroniew, 2009; Sofroniew and Vinters,
2010). Thesemodifications, which involve gain and loss of cellular func-
tions, may have both beneficial and detrimental effects on the sur-
rounding tissue. The progression in the process of astrogliosis, which
is regulated by multiple extracellular signals and multiple intracellular
signaling cascades (Sofroniew, 2009; Sofroniew and Vinters, 2010),
may turn a neuron-protective astrocyte into a proinflammatory,
neuron-damaging cell. Acute reactive gliosis and acute inflammation
are considered adaptive responses that contribute to minimize neuro-
nal damage. However, chronic gliosis and inflammation may enhance
neuronal damage and amplify the neurodegenerative process
(Sofroniew, 2009; Graeber and Streit, 2010; Lull and Block, 2010). It is
therefore important to understand how reactive gliosis and local in-
flammation are regulated in the CNS and to identify the factors involved
in this regulation. In this review we will focus on the role of gonadal
hormones as regulatory factors of the process of microgliosis, astroglio-
sis and local inflammation in the CNS.
Control of reactive gliosis by progesterone
It is well documented that progesterone exerts neuroprotective
actions in the brain and the spinal cord under different pathological
conditions, such as traumatic brain injury, spinal cord transection,
multiple sclerosis and stroke (Garay et al., 2007, 2008, 2009; De
Nicola et al., 2009; Sayeed and Stein, 2009; Stein and Wright, 2010;
Feeser and Loria, 2011; Hussain et al., 2011; Labombarda et al.,
2011). Part of the neuroprotective actions of progesterone may in-
volve the control of reactive gliosis and the inflammatory response
of glial cells, upregulating anti-inflammatory cytokines and down-
regulating proinflammatory mediators (Sayeed and Stein, 2009;
Stein and Wright, 2010; Yates et al., 2010; Feeser and Loria, 2011).
For instance, progesterone reduces the production of nitric oxide
and the expression of inflammatory cytokines, such as tumor necrosis
factor (TNF)-α and interleukin (IL)-1β, in cultured microglia exposed
to lipopolysaccharide (LPS) (Drew and Chavis, 2000; Jiang et al.,
2011). In vivo studies have shown that progesterone alone (Jiang
et al., 2011), or in combination with estradiol (Dang et al., 2011),
reduces the activation of microglia in experimental models of stroke
in rats. Progesterone reduces also the proliferation and the size of
GFAP immunoreactive astrocytes and regulates local brain inflammato-
ry response after traumatic or penetrating brain injury in rats (Garcia-
Estrada et al., 1993, 1999; Djebaili et al., 2005; VanLandingham et al.,
2007; Feeser and Loria, 2011). Similar effects have been obtained with
its precursor pregnenolone (García-Estrada et al., 1999). Progesterone
also reduces reactive astroglia and reactive microglia after spinal cord
transection (Labombarda et al., 2011). Reduction of astrogliosis by pro-
gesterone has been also detected in the spinal cord of Wobbler mouse(Meyer et al., 2010), an animalmodel ofmotoneurondegeneration. Fur-
thermore, progesterone reduces microglia activation in a model
of demyelination in the spinal cord (Garay et al., 2011). Therefore, the
actions of progesterone on different experimental models of CNS pa-
thology involve the control of reactive astroglia and reactive microglia.
Control of reactive gliosis by androgens
Protective actions of androgens have been identified in some neuro-
degenerative diseases such as multiple sclerosis (Gold and Voskuhl,
2009), Alzheimer's disease (Pike et al., 2009) and focal cerebral ischemia
(Pan et al., 2005; Uchida et al., 2009). Androgens also protect motoneu-
rons from axotomy (Fargo et al., 2009). However, detrimental neurolog-
ical effects of androgens have also been described after brain ischemia
(Yang et al., 2002; Cheng et al., 2007; Nakano et al., 2010) and androgens
increase damage in spinal and bulbar muscular atrophy, a disorder
causedby abnormal polyglutaminationof androgen receptor and charac-
terized by spinal cord and brain stem motoneuron loss (Parodi and
Pennuto, 2011). The actions of androgens on reactive gliosis have not
been systematically explored yet. However, available evidence indicates
that testosteronedecreases reactive astroglia and reactivemicroglia after
a stab wound injury in the brain (Garcia-Estrada et al., 1993, 1999;
Barreto et al., 2007). Testosterone also decreases astrogliosis associated
to motoneuron axotomy (Coers et al., 2002; Storer and Jones, 2003).
The adrenal androgen and testosterone precursor, dehydroepian-
drosterone (DHEA), also regulates reactive gliosis. DHEA reduces the
inflammatory response in LPS-stimulated microglia (Wang et al.,
2001) and mycoplasma-stimulated astrocytes (Kipper-Galperin et
al., 1999). In vivo, it has been shown that DHEA reduces microglia
activation in the striatum in a rat model of Parkinson's disease
(Tomas-Camardiel et al., 2002) and downregulates astrogliosis after
a penetrating brain injury (García-Estrada et al., 1999) and after
denervation of the olfactory bulb (Hoyk et al., 2004).
Control of reactive gliosis by estradiol
Neuroprotective actions of estradiol have been characterized
in numerous experimental models of neurodegenerative diseases
in vitro and in vivo (Garcia-Segura et al., 2001; Bourque et al., 2009;
Lebesgue et al., 2009; Pike et al., 2009; Azcoitia et al., 2011; Scott
et al, 2012). In several of these models the hormone has been
shown to regulate the number of reactive microglia and the number
of reactive astrocytes. For instance, estradiol reduces microglia reac-
tivity after traumatic injury of the brain (Barreto et al., 2007) or the
spinal cord (Sribnick et al., 2005), after the intracerebroventricular
or the systemic administration of LPS (Vegeto et al., 2001, 2003,
2006, 2008; Tapia-Gonzalez et al., 2008) and after the experimental
induction of central demyelination by the administration of cuprizone
(Taylor et al., 2010). Microglia reactivity is also reduced after estradiol
treatment in the oculomotor nucleus after peripheral axotomy
(Gyenes et al., 2010), in the substantia nigra pars compacta in a
mouse model of Parkinson's disease (Tripanichkul et al., 2006) and
in the brain of APP23 mice, an Alzheimer's disease model (Vegeto et
al., 2006). The hormone not only reduces the number of activated
microglia but also their response to inflammatory stimuli, such as
LPS or pro-inflammatory cytokines, decreasing their phagocytic activ-
ity and the production of TNFα and inducible nitric oxide (Drew and
Chavis, 2000; Bruce-Keller et al., 2000, 2001; Vegeto et al., 2000,
2001; Baker et al., 2004; Dimayuga et al., 2005; Johnson and Sohrabji,
2005; Liu et al., 2005).
Astrogliosis is also regulated by estradiol. Depending on the region
of the central nervous system and on the pathological condition,
estradiol decreases or increases the number of astrocytes. Thus, the
hormone decreases astrocytosis in the cerebral cortex and the
hippocampus after stab wound injuries (Garcia-Estrada et al., 1993,
1999; Barreto et al., 2007, 2009; López Rodríguez et al., 2011), in
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rons (Martinez and de Lacalle, 2007), in the hippocampus after the
administration of kainic acid (Ciriza et al., 2004b) and in the substan-
tia nigra pars compacta in a Parkinson's disease animal model
(Tripanichkul et al., 2006). In contrast, the combined treatment of es-
tradiol and progesterone increases the proliferation of astrocytes in
the corpus callosum after the induction of demyelination by cupri-
zone (Acs et al., 2009; Kipp and Beyer, 2009). Furthermore, estradiol
increases astrocytosis in the spinal cord after mechanical injury
(Ritz and Hausmann, 2008) and in the olfactory bulb after excitotoxic
injury (Lewis et al., 2008). The causes for these differences in the
effect of estradiol on reactive astrocytes are unknown. However, the
effect of gonadal hormones on the number of reactive astrocytes in
the cuprizone demyelination model is correlated with an increase in
the levels of insulin-like growth factor-I (IGF-I), a trophic factor
produced by astrocytes that promotes oligodendrocyte proliferation
and differentiation (Acs et al., 2009; Kipp and Beyer, 2009). Thus,
while under some circumstances estradiol reduces astrogliosis
and the expression of proinflammatory molecules by astrocytes
(Kipp et al., 2007; Tenenbaum et al., 2007; Dodel et al., 1999;
Cerciat et al., 2010; Rubio et al., 2011), in other conditions the
hormone increases astrogliosis and the glial production of trophic
factors that promote neuronal survival and remyelination (Sortino
et al., 2004; Dhandapani et al., 2005; Kipp and Beyer, 2009).
Role of steroid metabolism and signaling mechanisms involved in
the regulation of reactive gliosis by gonadal hormones
Gonadal hormones aremetabolized by neural tissue to neuroactive
steroids that act by a variety of signaling mechanisms (Garcia-Segura
and Melcangi, 2006; Melcangi et al., 2008). These metabolites may
mediate some of the effects of gonadal hormones in the nervous sys-
tem, including the control of reactive gliosis. For instance, the control
exerted by progesterone on reactive gliosis may be in part mediated
by its reduced metabolites, such as allopregnanolone (Ciriza et al.,
2004a; Djebaili et al., 2005; Ciriza et al., 2006; VanLandingham et al.,
2007), which modulates the activity of GABAA receptors (Belelli
et al., 2006). Allopregnanolone reduces reactive gliosis in different
brain injury models (Ciriza et al., 2004a; Djebaili et al., 2005; Ciriza
et al., 2006; VanLandingham et al., 2007) and the inhibition of proges-
teronemetabolism to allopregnanolone blocks the antigliotic action of
the hormone in rats injected with kainic acid (Ciriza et al., 2006).
The effect of testosterone on reactive astroglia and reactive micro-
glia after a stab wound injury in the brain may also be in part mediat-
ed by its metabolites. Testosterone is converted to estradiol, a ligand
of estrogen receptors, by the enzyme aromatase and to dihydrotes-
tosterone (DHT), a ligand of androgen receptor, by the enzyme
5α-reductase. Both enzymes are expressed in the CNS (Martini et
al., 1996). The treatment of orchidectomized rats with testosterone
reduces the number of reactive astrocytes and reactive microglia in
the border of a penetrating lesion in the hippocampus. This effect is
observed both when the treatment is initiated immediately after the
injury and when it is initiated five days later (Barreto et al., 2007).
The effects of testosterone on reactive astrocytes and reactive micro-
glia are fully reproduced by estradiol (Barreto et al., 2007). In con-
trast, the non-aromatizable testosterone metabolite DHT reproduces
the effect of testosterone on reactive microglia but not on reactive as-
trocytes and only when the treatment with DHT is initiated immedi-
ately after injury (Barreto et al., 2007). These findings suggest that the
antigliotic action of testosterone in this model may be mediated by its
metabolites and mainly by its conversion to estradiol.
The antigliotic effects of the testosterone precursor DHEAmay also
be mediated by its metabolites. For instance, the inhibition of aroma-
tase blocks the effect of DHEA on reactive astrocytes in the olfactory
bulb (Hoyk et al., 2004), suggesting that the antigliotic action of
DHEA in this brain region is mediated by estrogens. Anothermetabolite of DHEA that reduces the inflammatory response of glial
cells is 5-androsten-3β, 17β-diol (ADIOL), which is a selective modu-
lator of estrogen receptor (ER)β (Saijo et al., 2011).
In vitro studies have shown that both ERα and ERβ selective ago-
nists reduce the inflammatory response of microglia to LPS (Smith
et al., 2011). However, in general, estrogenic compounds with a pre-
dominant ERβ profile are more potent in reducing the inflammatory
response of astrocytes and microglia in vitro (Lewis et al., 2008).
Furthermore, estradiol has anti-inflammatory actions in the murine
microglial cell line BV-2, which express ERβ and not ERα (Baker
et al., 2004) and, as previously mentioned, the ERβ agonist ADIOL re-
duces the inflammatory response of microglia and astroglia in vitro
(Saijo et al., 2011). These findings indicate that ERβ is involved in
the control of inflammation exerted by estradiol acting directly on as-
trocytes and microglia. In addition, ERα is also involved in the actions
of estradiol on microglia and astrocytes. Thus, the anti-inflammatory
actions of estradiol on microglia after intracerebral injection of LPS
are lost in ERαKO mice (Vegeto et al., 2003). In addition, expression
of ERα in astrocytesmediates the anti-inflammatory actions of estradiol
on experimental autoimmune encephalomyelitis (Tiwari-Woodruff et
al., 2007; Spence et al., 2011). Therefore, ERα participates in the anti-
inflammatory actions of estradiol in the CNS in vivo.
The action of ERα on the control of neural inflammation is
mediated by the regulation of NFkappaB-mediated transcription of
inflammatory molecules. Thus, the activation of ERα results in the
inhibition of NFkappaB nuclear translocation in macrophages and
microglia by a mechanism mediated by phosphatidylinositol 3-
kinase (Ghisletti et al., 2005; Pozzi et al., 2006). In addition, ERα is
also involved in the direct repression of NFkappaB-dependent
transcription in astrocytes (Giraud et al., 2010). In contrast, ADIOL
and other ERβ ligands reduce the expression of proinflammatory
genes by inducing the recruitment of the transcriptional corepressor
c-terminal binding protein (CtBP) to proinflammatory promoters
(Saijo et al., 2011). Therefore, ERα and ERβ control the inflammatory
response of glial cells by complementary mechanisms. It is possible
that the relative role of ERα and ERβ on the control of the neural in-
flammatory response in vivowould depend both on the type of injury
and on the CNS region considered.
Perspectives for the future
Recent studies have identified additional molecules that partici-
pate in the control of reactive gliosis by gonadal hormones. However,
the mechanisms involved in the interaction of gonadal hormones
with these molecules remain to be explored and characterized. One
of such molecules is the product of the Parkinson's disease related
gene parkin. The control of astrogliosis and microgliosis exerted by
estradiol in vitro is lost in midbrain cultures from parkin null mice
(Rodríguez-Navarro et al., 2008). Parkin may mediate the action of
estradiol on gliosis by the regulation of ERα turnover (Rodríguez-
Navarro et al., 2008), by enhancing anti-inflammatory IGF-I signaling
(Bellini et al., 2011; Akundi et al., 2012) or by regulating the expres-
sion of mitochondrial proteins (Pilsl and Winklhofer, 2012).
The endocannabinoid system has also been recently identified as
one of the targets of estradiol for the regulation of reactive gliosis.
The hormone increases the expression of CB2 receptors and regulates
the expression of some of the enzymes involved in the synthesis and
metabolism of endocannabinoids in the cerebral cortex after brain
injury (López Rodríguez et al., 2011). In addition, both CB1 and CB2
receptor antagonists reduce the action of estradiol on reactive astro-
cytes in the injured cerebral cortex (López Rodríguez et al., 2011).
The precise mechanisms of the interaction of estradiol with the endo-
cannabinoid system in the regulation of reactive gliosis remain to be
elucidated. The interaction of estradiol with other signaling molecules
that regulate reactive gliosis, such as purinergic receptors (Crain and
Watters, 2010), merits also to be explored.
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pation of peripheral inflammation on the regulation of gliosis by gonad-
al hormones. For instance, it has been shown that the putative
membrane estrogen receptor G protein-coupled receptor 30 (GPR30)
contributes to the control of inflammation in experimental autoim-
mune encephalomyelitis by actions on peripheral immune cells
(Blasko et al., 2009). Thus, the final effect of gonadal hormones on the
control of reactive gliosis and CNS inflammationmay result from a com-
bination of central and peripheral actions.
The existence of sex differences in the response of glial cells to in-
flammatory and neurodegenerative conditions is also a highly rele-
vant issue, because glial cells may contribute to sex differences in
the manifestation of neurodegenerative diseases. This question has
recently received some attention and sex differences in the response
of astrocytes and microglia to neurodegeneration and inflammation
as well as sex differences in the regulation of reactive gliosis by go-
nadal hormones have been reported (Dasgupta et al., 2005; Doherty
et al., 2007; Liu et al., 2007; Cordeau et al., 2008; Crain and Watters,
2010; Santos-Galindo et al., 2011; Sundar Boyalla et al., 2011). How-
ever, further studies are required to determine the precise mecha-
nisms and the functional consequences of the sex differences in the
response of glial cells under pathological conditions.
Another relevant point is whether aging affects the antigliotic ac-
tivity of gonadal hormones. Aging per se affects glial cells (Godbout
and Johnson, 2009). Thus, microglia cells from aged animals exhibit
an altered inflammatory profile (Sierra et al., 2007) and the astroglial
response after brain injury is enhanced in aged animals (Barreto et al.,
2009). The regulation of inflammatory molecules by estradiol in the
CNS is also affected by aging (Nordell et al., 2003; Johnson and
Sohrabji, 2005) and this may impair the neuroprotective actions of
the ovarian hormone in older animals. However, estradiol and other
estrogenic compounds are still able to reduce the number of reactive
astrocytes in aged animals and in a rat model of menopause, even
after a long period of ovarian hormone deprivation (Lei et al., 2003;
Barreto et al., 2009).
The most important question that remains to be clarified is the
functional outcome of the regulation of reactive gliosis by gonadal
hormones. Reactive astrocytes release different molecules that pro-
mote neuronal survival, such as IGF-I (Acs et al., 2009; Kipp and
Beyer, 2009), transforming growth factor beta (Sortino et al., 2004;
Dhandapani et al., 2005) and neuroprotective steroids, including
estradiol (Garcia-Ovejero et al., 2005; Garcia-Segura and Melcangi,
2006). Therefore, in addition to decrease local inflammation, the
downregulation of reactive gliosis by gonadal hormones after some
forms of CNS injury may also potentially reduce the local production
and release of neuroprotective factors by reactive astrocytes. Further
studies aimed to the identification of the molecular phenotype of
the astrocytes and microglia regulated by gonadal hormones after
CNS injury are necessary.
Finally, although gonadal hormones regulate gliosis, their therapeu-
tic use to reduce brain inflammation is limited by their peripheral effects,
in particular for estradiol and testosterone. For this reason, the antigliotic
activity of hormone analogs, such as different selective estrogen receptor
agonists ormodulators andnon-feminizing estrogens, is currently under
study (Saijo et al., 2011; Smith et al., 2011; Arevalo et al., 2012).
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